30-day average of 18 articles Β· scale β100 to +100
Across 18 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of Bristol-Myers Squibb Company news is Somewhat Bullish (+40)
on a scale from β100 to +100.
That is up 10 points from the previous 30 days (+30).
π BMY stock returned 40.5% over three years, trading near $62.91.
π° Company generated $9.3 billion in free cash flow last twelve months.
Slightly Bullish +15
Bristol Myers Squibb (BMY) Stock Looks Below Fair Value Following A 41% ...
AI-generated analysis
Key insights
π BMY stock has returned approximately 40.5% over the past three years, trading near $62.91 per share.
π° The company generated about $9.3 billion in free cash flow over the last twelve months according to the analysis.
π¬ Recent positive data for Camzyos and new approvals for ZENBEXUS are expected to support future drug-driven cash flows.
β οΈ Investors face a projected revenue step-down from Eliquis beginning in 2027 as part of the company's lifecycle management.
π‘ A bullish narrative suggests BMY is 21% undervalued if late-stage platforms like CAR-T and ADCs succeed commercially.
π A bearish perspective argues the stock is 121% overvalued at current levels, with price being the primary sticking point.
πΈ The company has implemented a plan to generate $2 billion in cost savings to offset revenue shifts.
π§ Simply Wall St analysis indicates the fair value depends on successfully converting late-stage platforms into meaningful products.
π Bullish signals
π¬Recent trial results for Camzyos and new product approvals for ZENBEXUS are expected to support expectations for future drug-driven cash flows.
π‘The company has a solid pipeline story with late-stage platforms in areas like CELMoDs, CAR-T, ADCs, Factor XI inhibition, and neuroscience that could convert into commercially meaningful products.
π‘A bullish analyst narrative suggests the stock is 21% undervalued if the company successfully manages revenue transitions from legacy assets like Eliquis.
π Risk factors
π°The DCF model assumes a gently declining free cash flow pattern over the next decade as major products mature and new launches fill gaps only gradually.
πA bearish investor narrative argues the stock is 121% overvalued at current levels, stating that the entry price exceeds fair value filters despite the company's quality.
β οΈThe analysis projects a step-down in revenue from Eliquis starting in 2027, which constrains growth assumptions in the valuation model.
Article
Bristol-Myers Squibb (BMY) shares have appreciated approximately 40.5% over the past three years, trading around $62.91 per share. The article analyzes whether this valuation is justified by the company's long-term cash flow generation capabilities, utilizing a Discounted Cash Flow (DCF) model that projects free cash flow of roughly $9.3 billion over the last twelve months.
The analysis suggests BMY may be undervalued based on intrinsic value calculations derived from its cash flow profile. Key drivers supporting this view include recent positive trial results for Camzyos and new product approvals for ZENBEXUS, which are expected to bolster future drug-driven cash flows despite anticipated revenue declines from the legacy asset Eliquis starting in 2027.
Simply Wall St presents a split narrative regarding BMY's fair value. A bullish perspective argues the stock is 21% undervalued if the company successfully commercializes its late-stage platforms in areas like CAR-T and ADCs while managing revenue transitions. Conversely, a bearish view contends the stock is 121% overvalued at current levels, citing that the entry price exceeds fair value filters despite the underlying quality of the business.
The article concludes by emphasizing the importance of leadership strategy in shaping BMY's future trajectory. It notes that while the company has a solid pipeline and cost-saving plans totaling $2 billion, investors must weigh these factors against the specific assumptions regarding growth margins and earnings required to justify the current market price.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Drug approvalEarnings reportFinancial outlookAI-generated analysis
Bristol-Myers Squibb (BMY) shares have appreciated approximately 40.5% over the past three years, trading around $62.91 per share. The article analyzes whether this valuation is justified by the company's long-term cash flow generation capabilities, utilizing a Discounted Cash Flow (DCF) model that projects free cash flow of roughly $9.3 billion over the last twelve months.
The analysis suggests BMY may be undervalued based on intrinsic value calculations derived from its cash flow profile. Key drivers supporting this view include recent positive trial results for Camzyos and new product approvals for ZENBEXUS, which are expected to bolster future drug-driven cash flows despite anticipated revenue declines from the legacy asset Eliquis starting in 2027.
Simply Wall St presents a split narrative regarding BMY's fair value. A bullish perspective argues the stock is 21% undervalued if the company successfully commercializes its late-stage platforms in areas like CAR-T and ADCs while managing revenue transitions. Conversely, a bearish view contends the stock is 121% overvalued at current levels, citing that the entry price exceeds fair value filters despite the underlying quality of the business.
The article concludes by emphasizing the importance of leadership strategy in shaping BMY's future trajectory. It notes that while the company has a solid pipeline and cost-saving plans totaling $2 billion, investors must weigh these factors against the specific assumptions regarding growth margins and earnings required to justify the current market price.
π BMY stock returned 40.5% over three years, trading near $62.91.
π° Company generated $9.3 billion in free cash flow last twelve months.
π¬ Positive data for Camzyos and ZENBEXUS approvals support future cash flows.
β οΈ Eliquis revenue step-down projected to begin in 2027.
π BMY stock has returned approximately 40.5% over the past three years, trading near $62.91 per share.
π° The company generated about $9.3 billion in free cash flow over the last twelve months according to the analysis.
π¬ Recent positive data for Camzyos and new approvals for ZENBEXUS are expected to support future drug-driven cash flows.
β οΈ Investors face a projected revenue step-down from Eliquis beginning in 2027 as part of the company's lifecycle management.
π‘ A bullish narrative suggests BMY is 21% undervalued if late-stage platforms like CAR-T and ADCs succeed commercially.
π A bearish perspective argues the stock is 121% overvalued at current levels, with price being the primary sticking point.
πΈ The company has implemented a plan to generate $2 billion in cost savings to offset revenue shifts.
π§ Simply Wall St analysis indicates the fair value depends on successfully converting late-stage platforms into meaningful products.
Bullish Signals
Camzyos and ZENBEXUS approvals support future drug cash flows.
Solid pipeline in CELMoDs, CAR-T, ADCs, Factor XI, neuroscience.
Bullish view: 21% undervalued if Eliquis revenue transitions succeed.
Risk Factors
DCF assumes gradual FCF decline as products mature.
Stock deemed 121% overvalued by bearish investors.
Eliquis revenue projected to step down starting 2027.
Bullish Signals
Recent trial results for Camzyos and new product approvals for ZENBEXUS are expected to support expectations for future drug-driven cash flows.
The company has a solid pipeline story with late-stage platforms in areas like CELMoDs, CAR-T, ADCs, Factor XI inhibition, and neuroscience that could convert into commercially meaningful products.
A bullish analyst narrative suggests the stock is 21% undervalued if the company successfully manages revenue transitions from legacy assets like Eliquis.
Risk Factors
The DCF model assumes a gently declining free cash flow pattern over the next decade as major products mature and new launches fill gaps only gradually.
A bearish investor narrative argues the stock is 121% overvalued at current levels, stating that the entry price exceeds fair value filters despite the company's quality.
The analysis projects a step-down in revenue from Eliquis starting in 2027, which constrains growth assumptions in the valuation model.
Drug approvalEarnings reportFinancial outlookAI-generated analysis
Bristol-Myers Squibb (BMY) shares have appreciated approximately 40.5% over the past three years, driven by positive data for key therapies and a robust pipeline. The stock recently closed at US$62.91, prompting analysts to evaluate whether this valuation is supported by the company's long-term cash generation capabilities.
A Discounted Cash Flow (DCF) analysis indicates that BMY's intrinsic value is substantially higher than its current market price of $62.91. The model projects free cash flow of roughly $9.3 billion over the last twelve months, assuming a gradual decline as legacy products like Eliquis face revenue steps starting in 2027, partially offset by new launches.
Community analysts on Simply Wall St present divergent views on BMY's valuation. A bullish narrative suggests the stock is 21% undervalued if the company successfully commercializes late-stage platforms in areas such as CAR-T and ADCs while managing legacy declines. Conversely, a bearish perspective argues the stock is 121% overvalued at current levels, citing that the entry price exceeds fair value filters despite the company's clear quality.
The divergence in opinion highlights a split between investors focused on BMY's growing late-stage portfolio and those concerned with the current share price relative to intrinsic value. The article concludes by noting that leadership strategy and prioritization will be critical factors in determining whether BMY can bridge the gap between its discounted cash flow estimates and market pricing.
π BMY shares gained 40.5% over three years, trading at US$62.91.
π° Company generated roughly $9.3 billion in free cash flow last year.
π Revenue expected to decline from Eliquis starting in 2027.
π New approvals for Camzyos and ZENBEXUS will support future cash flows.
π¬ BMY develops late-stage platforms in CELMoDs, CAR-T, ADCs, and neuroscience.
π BMY shares have returned approximately 40.5% over the past three years, trading at US$62.91.
π° The company generated about $9.3 billion in free cash flow over the last twelve months.
π Analysts project a revenue step-down from Eliquis starting in 2027 as major products mature.
π New product approvals for Camzyos and ZENBEXUS are expected to support future drug-driven cash flows.
π¬ The company is developing late-stage platforms in CELMoDs, CAR-T, ADCs, Factor XI inhibition, and neuroscience.
π‘ A bullish community narrative values BMY at 21% undervalued based on successful platform conversion.
β οΈ A bearish community narrative considers BMY 121% overvalued due to the current entry price exceeding fair value filters.
π DCF models suggest intrinsic value is substantially above the current share price of $62.91.
Bullish Signals
Share price rose 40.5% over three years.
Camzyos trials and ZENBEXUS approvals boost cash flow.
Analysts see 21% undervaluation if platforms succeed.
Risk Factors
Eliquis revenue step-down from 2027 restrains growth assumptions.
Stock deemed 121% overvalued by bearish community.
Bullish Signals
The company has delivered a strong 40.5% share price return over the past three years, indicating market confidence in its trajectory.
Recent trial results for Camzyos and new product approvals for ZENBEXUS support expectations for future drug-driven cash flows.
A bullish analyst narrative suggests BMY is 21% undervalued if the company successfully converts late-stage platforms into commercially meaningful products.
Risk Factors
The projected step-down in revenue from Eliquis starting in 2027 necessitates restrained growth assumptions in valuation models.
A bearish community narrative argues the stock is 121% overvalued at current levels, suggesting the entry price exceeds fair value filters.
Bristol Myers Squibb (BMY) received positive attention following the presentation of 56-week data from the Phase 3 SCOUT-HCM trial for its drug Camzyos (mavacamten). The study, presented at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions in Chicago, focused on adolescents aged 12 to under 18 with symptomatic obstructive hypertrophic cardiomyopathy. These results extend the evidence base for Camzyos shortly after the FDA granted pediatric approval in September 2026 for patients weighing at least 30 kilograms.
The trial enrolled 44 patients, with most receiving continuous treatment with mavacamten. At Week 56, the group recorded a mean reduction in Valsalva LVOT-gradient of -48.1 mmHg, indicating significant improvement in blood flow obstruction. Safety findings remained consistent with earlier data, showing no new safety signals and no instances of left ventricular ejection fraction dropping below 50% during the evaluation period.
The company highlighted that the longer-term data supports the continued evaluation of Camzyos in this pediatric population. While the trial remains a clinical efficacy study rather than a financial forecast, the findings bolster the commercial reach of the cardiovascular medicine by validating its use in adolescents. This development reinforces BMY's position in treating obstructive hypertrophic cardiomyopathy across adult and pediatric demographics.
π BMY presents positive 56-week SCOUT-HCM trial results for Camzyos in adolescents.
π¬ Study of 44 patients showed mean LVOT-gradient reduction of -48.1 mmHg.
β Safety remained consistent with no new signals or EF drop below 50%.
π Bristol Myers Squibb presented positive 56-week results from the SCOUT-HCM trial for Camzyos in adolescents with symptomatic obstructive hypertrophic cardiomyopathy.
π¬ The study enrolled 44 patients aged 12 to under 18, demonstrating a mean Valsalva LVOT-gradient reduction of -48.1 mmHg after continuous mavacamten treatment.
β Safety data remained consistent with prior results, with no new signals and no drop in left ventricular ejection fraction below 50% for any patient.
π₯ The FDA previously approved Camzyos for pediatric patients weighing at least 30 kilograms in September 2026 based on earlier trial data.
πΌ The findings extend the commercial reach of Camzyos by validating its efficacy and safety in a younger demographic with obstructive hypertrophic cardiomyopathy.
π Bristol Myers Squibb shares traded at 55.65 euros, reflecting investor focus on the company's cardiovascular portfolio updates.
Bullish Signals
SCOUT-HCM trial showed -48.1 mmHg gradient reduction in adolescents.
Drug maintained safety with no new signals over 56 weeks.
FDA approval extends Camzyos use to adolescents weighing 30kg+.
Bullish Signals
Bristol Myers Squibb presented robust 56-week data from the SCOUT-HCM trial showing a mean Valsalva LVOT-gradient reduction of -48.1 mmHg in adolescents treated with Camzyos.
The drug demonstrated consistent safety profiles over 56 weeks with no new safety signals and no instances of left ventricular ejection fraction falling below 50%.
Positive pediatric data extends the commercial reach of Camzyos, validating its use in adolescents following the FDA's September 2026 approval for patients weighing at least 30 kilograms.
Bristol Myers Squibb presented new 56-week data from the Phase 3 SCOUT-HCM trial on Friday, November 6, at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions in Chicago. The study focused on adolescents aged 12 to under 18 with symptomatic obstructive hypertrophic cardiomyopathy, extending the drug's cardiovascular development story for this pediatric segment.
Continuous treatment with Camzyos (mavacamten) produced a mean reduction of 48.1 mmHg in the Valsalva left ventricular outflow tract gradient after 56 weeks. Patients who switched from placebo to Camzyos at week 28 achieved similar reductions, while meaningful improvements were observed in several secondary endpoints without any patient experiencing a left ventricular ejection fraction below 50 percent.
The U.S. Food and Drug Administration approved Camzyos for pediatric patients weighing at least 30 kilograms in September 2026. This expanded follow-up strengthens the evidence base for the newly eligible patient segment, though the small trial population of 44 patients and the need for continuing safety monitoring remain relevant factors for future uptake expectations.
Bristol Myers Squibb plans to present additional data covering clinical and real-world evidence at the American Heart Association Scientific Sessions through November 9. The company's stock traded at 55.50 euros on Lang & Schwarz on Monday, November 9, 2026, reflecting market reaction to the positive pediatric trial results.
π FDA approved Camzyos for pediatric patients weighing 30kg+ in September 2026.
β No patient dropped below 50% ejection fraction during the 56-week study.
π‘οΈ Safety data recorded five treatment-related adverse events in continuous-treatment group.
π° Stock traded at 55.50 euros on November 9, 2026 after positive results.
π Bristol Myers Squibb presented 56-week Phase 3 SCOUT-HCM trial data showing a mean 48.1 mmHg reduction in Valsalva left ventricular outflow tract gradient for adolescents with symptomatic obstructive hypertrophic cardiomyopathy.
πΆ The study included 44 patients aged 12 to under 18, with continuous Camzyos treatment or a switch from placebo at week 28 demonstrating similar efficacy in reducing the left ventricular outflow tract gradient.
β No patient experienced a left ventricular ejection fraction below 50 percent during the 56-week evaluation, indicating maintained cardiac function across the treatment groups.
π‘οΈ Safety data showed five treatment-related adverse events and two serious events in the continuous-treatment group, with no serious events recorded in the crossover group during its active-treatment period.
π The U.S. Food and Drug Administration approved Camzyos for pediatric patients weighing at least 30 kilograms in September 2026, validating the drug's use in this new demographic.
ποΈ Bristol Myers Squibb plans to present additional clinical and real-world evidence regarding Camzyos at the American Heart Association Scientific Sessions through November 9.
π° The stock traded at 55.50 euros on Lang & Schwarz on November 9, 2026, following the presentation of positive pediatric trial results.
Bullish Signals
Camzyos reduced LVOT gradient by 48.1 mmHg in adolescents after 56 weeks.
Phase 3 SCOUT-HCM trial supports pediatric use for patients weighing 30kg+.
Switching from placebo showed similar efficacy regardless of prior treatment exposure.
No patient had LVEF drop below 50% during the 56-week evaluation.
Risk Factors
Small trial of 44 patients limits generalizability.
Study showed 5 adverse events and 2 serious ones.
Bullish Signals
Bristol Myers Squibb demonstrated strong efficacy in adolescents with symptomatic obstructive hypertrophic cardiomyopathy, achieving a mean 48.1 mmHg reduction in Valsalva left ventricular outflow tract gradient after 56 weeks of continuous Camzyos treatment.
The Phase 3 SCOUT-HCM trial results strengthen the evidence base for Camzyos in a newly eligible pediatric patient segment, following FDA approval for patients weighing at least 30 kilograms in September 2026.
Patients who switched from placebo to Camzyos at week 28 achieved similar reductions in the left ventricular outflow tract gradient, confirming the drug's efficacy regardless of prior treatment exposure.
The trial reported meaningful improvements in several secondary endpoints without any patient experiencing a decline in left ventricular ejection fraction below 50 percent during the 56-week evaluation.
Risk Factors
The small trial population of only 44 patients may limit the generalizability of the results and necessitate further studies to confirm efficacy and safety in a broader adolescent population.
Continuing safety monitoring remains relevant for expectations regarding uptake, as the study included five treatment-related adverse events and two serious events in the continuous-treatment group.
Bristol Myers Squibb presented new 56-week clinical data for its drug Camzyos (mavacamten) in pediatric patients with symptomatic obstructive hypertrophic cardiomyopathy at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions. The Phase 3 SCOUT-HCM trial evaluated the safety and efficacy of the treatment over a longer duration than previously reported, confirming consistent performance in this younger demographic.
The study included 44 randomized patients aged 12 to under 18, with 43 completing the double-blind placebo-controlled period. Results showed that patients receiving Camzyos achieved a mean reduction of 48.1 mmHg in the Valsalva left ventricular outflow tract gradient after 56 weeks. Patients who switched from placebo to active treatment demonstrated similar degrees of improvement, indicating robust therapeutic response.
Safety profiles remained stable throughout the evaluation period, with no patient experiencing a left ventricular ejection fraction below 50%. The company reported no new safety signals and noted that treatment-emergent adverse events and serious events remained low. This data supports the September 2026 FDA approval for pediatric patients weighing at least 30 kilograms and strengthens the drug's developing profile in this specific market segment.
Further presentations regarding Camzyos are scheduled for the American Heart Association Scientific Sessions through November 9, covering additional clinical and real-world evidence in adult patients. These upcoming events will provide further context on long-term safety and effectiveness analyses, complementing the new pediatric findings presented in Chicago.
π FDA approved Camzyos in Sept 2026 for pediatric patients weighing at least 30 kg.
π¬ Study confirmed mean reduction of 48.1 mmHg in Valsalva gradient after 56 weeks.
π‘οΈ Safety remained consistent with no new signals or drops in ejection fraction.
π£οΈ Additional adult patient data presentations scheduled through Nov 9 at AHA sessions.
π Bristol Myers Squibb released positive 56-week SCOUT-HCM trial data for Camzyos in pediatric patients with symptomatic obstructive hypertrophic cardiomyopathy.
π¬ The study confirmed a mean reduction of 48.1 mmHg in the Valsalva left ventricular outflow tract gradient after 56 weeks of treatment.
π‘οΈ Safety remained consistent with no new signals reported and no patients dropping below a 50% left ventricular ejection fraction during the evaluation.
π The FDA approved Camzyos in September 2026 for pediatric patients weighing at least 30 kilograms based on earlier positive results.
π£οΈ Additional clinical presentations covering adult patient data are scheduled for the American Heart Association Scientific Sessions through November 9.
Bullish Signals
Phase 3 SCOUT-HCM trial showed consistent efficacy in pediatric patients over 56 weeks.
Drug reduced Valsalva gradient by 48.1 mmHg, validating therapeutic impact on HCM.
No new safety signals emerged; adverse events remained low for pediatric use.
Bullish Signals
Bristol Myers Squibb demonstrated consistent efficacy and safety in its Phase 3 SCOUT-HCM trial for pediatric patients over a 56-week evaluation period.
The drug achieved a significant mean reduction of 48.1 mmHg in the Valsalva left ventricular outflow tract gradient, validating its therapeutic impact on obstructive hypertrophic cardiomyopathy.
No new safety signals emerged during the extended study, and treatment-emergent adverse events remained low, reinforcing the drug's favorable risk profile for pediatric use.
AI partnershipLicensing agreementResearch milestoneAI-generated analysis
Bristol Myers Squibb (BMY) has entered a strategic collaboration with Pathos AI and Tempus to integrate artificial intelligence and patient data into its neuroscience research pipeline. Announced on October 23, 2026, the deal grants BMY three-year exclusive rights to utilize the Pathos Foundry platform for Alzheimer's and other neurological programs, leveraging a de-identified longitudinal dataset covering hundreds of thousands of patients.
Under the terms of the agreement, Pathos AI will license this Tempus dataset under a five-year contract valued at 55 million US dollars. The collaboration aims to enhance disease biology examination, test research hypotheses, and facilitate more targeted, adaptive clinical trials. Additionally, Bristol Myers Squibb is leading Pathos AI's 237 million US dollar Series E financing round to support the expansion of the Foundry platform and its clinical-stage oncology pipeline.
The strategic update positions BMY to improve candidate selection, patient identification, and trial execution within its broader research and development portfolio. While the immediate stock price was noted at 56.23 euros on November 6, 2026, the long-term commercial payoff for Bristol Myers Squibb depends on whether this AI integration successfully accelerates drug development and yields tangible earnings improvements through regulatory milestones.
π€ BMY secures exclusive three-year rights to Pathos Foundry for neuroscience research.
π° Pathos AI licenses Tempus data under a five-year deal worth $55 million.
π BMY leads Pathos AI's $237 million Series E financing round.
Drug approvalRegulatory submissionAI-generated analysis
Bristol Myers Squibb (BMY) is shifting its strategic narrative from a primary focus on immuno-oncology to emphasizing newer drug platforms, specifically CELMoDs and radiopharmaceuticals. Management highlighted these platforms during its fiscal Q3 2026 earnings call in October 2026, citing strengthened conviction in targeted protein degradation technologies. The company is investing over $170 million into a new manufacturing facility in Indiana to support its radiopharmaceutical initiatives.
The article details the performance of BMY's key assets, noting that Opdivo remains the largest cancer drug with fiscal 2024 revenue of $9.3 billion, though it faced a 6% quarterly decline in Q3 2026 due to conversion to the newer Opdivo Qvantig formulation. Conversely, older therapies Revlimid and Pomalyst are experiencing significant sales declines, falling 48.9% and 22.9% respectively in fiscal 2025, creating a strategic need for new revenue drivers.
Management's strategy involves using CELMoDs to replace declining older drugs in the multiple myeloma market, with Zenbexus already approved and mezigdomide awaiting an FDA decision in May 2027. Analysts view this pivot as reassuring because it targets shrinking legacy sales, though risks remain regarding the timing of new drug approvals and the continued revenue transition from Opdivo to Qvantig ahead of the fiscal Q4 2026 report expected in February 2027.
π Investing $170M in Indiana facility for radiopharmaceuticals.
π Revlimid sales fell 48.9% in fiscal 2025 to $2.95B.
π¬ Zenbexus approved; mezigdomide decision expected May 13, 2027.
β οΈ Monitor combined Opdivo/Qvantig sales before Feb 2027 earnings.
π Bristol Myers Squibb is pivoting its strategic focus toward CELMoDs and radiopharmaceuticals, investing over $170 million in a new Indiana manufacturing facility for the latter.
π Opdivo remains the company's largest revenue driver with $9.3 billion in fiscal 2024 sales, though Q3 2026 revenue dipped 6% to $2.4 billion due to conversion to Opdivo Qvantig.
π Legacy cancer therapies Revlimid and Pomalyst are facing steep declines, with Revlimid sales falling 48.9% in fiscal 2025 to $2.95 billion.
π¬ The first CELMoD drug, Zenbexus (iberdomide), received accelerated FDA approval, while the second candidate, mezigdomide, is awaiting an FDA decision scheduled for May 13, 2027.
π― Management aims to make CELMoDs foundational in multiple myeloma treatment to replace older therapies like Revlimid and Pomalyst over time.
π Opdivo Qvantig generated $334 million in the third quarter of fiscal 2026, with management projecting annualized sales exceeding $1.3 billion.
β οΈ Investors are advised to monitor combined Opdivo and Qvantig sales closely as the primary metric for BMY's performance ahead of the fiscal Q4 2026 earnings report in February 2027.
Bullish Signals
Investing $170M in Indiana radiopharmaceutical facility.
Zenbexus gets accelerated FDA approval.
Opdivo Qvantig generates $334M in Q3 2026.
Risk Factors
Revlimid sales plummeted 48.9% in fiscal 2025.
Bullish Signals
Bristol Myers Squibb is investing over $170 million into a new radiopharmaceutical manufacturing facility in Indiana, signaling strong commitment to its emerging platform.
The company's first CELMoD drug, Zenbexus (iberdomide), has secured accelerated FDA approval, validating the efficacy of its targeted protein degradation technology.
Opdivo Qvantig is successfully transitioning from the legacy drug, generating $334 million in Q3 2026 with management projecting annualized sales over $1.3 billion.
Risk Factors
Legacy cancer therapies Revlimid and Pomalyst are shrinking rapidly, with Revlimid sales plummeting 48.9% in fiscal 2025, creating immediate pressure on top-line growth.
AI partnershipNew AI featuresAI-generated analysis
Bristol Myers Squibb (BMY) has expanded its artificial intelligence and data strategy in neuroscience through a new collaboration with Pathos AI. The partnership combines Pathos's AI capabilities, longitudinal patient data, and BMS's drug development expertise specifically to support Alzheimer's research and other neurological programs.
Under the terms of the agreement, Pathos will license access to a de-identified dataset covering hundreds of thousands of patients for five years at a cost of $55 million. This arrangement grants Bristol Myers Squibb non-exclusive strategic access to the Pathos Foundry platform across its broader R&D portfolio, while securing three-year exclusive rights within the neuroscience sector.
The collaboration aims to improve disease understanding, patient selection, and clinical trial design without providing immediate clinical efficacy data or a launch timetable. Additionally, BMY led Pathos AI's $237 million Series E financing round, valuing the company at approximately $3 billion, which will support the advancement of four clinical assets including the JSKN016 antibody-drug conjugate.
π€ BMY partners with Pathos AI to integrate AI into neuroscience research strategy.
π° Pathos licenses de-identified patient data for five years at $55 million cost.
π BMY secures three-year exclusive rights to Pathos Foundry platform for development.
πΈ BMY led $237M Series E financing, valuing Pathos AI at $3 billion.
π€ Bristol Myers Squibb partners with Pathos AI to integrate artificial intelligence and patient data into its neuroscience research strategy.
π° Pathos will license a de-identified dataset of hundreds of thousands of patients for five years at a cost of $55 million.
π BMS secures three-year exclusive rights to the Pathos Foundry platform specifically for its neuroscience development programs.
π§ The collaboration focuses on improving disease understanding, patient selection, and clinical trial design for Alzheimer's and other neurological conditions.
πΈ Bristol Myers Squibb led a $237 million Series E financing round for Pathos AI, valuing the partner at approximately $3 billion.
𧬠The funded capital will advance four clinical assets, including JSKN016, a TROP2/HER3 bispecific antibody-drug conjugate.
Bullish Signals
Partners with Pathos AI to expand neuroscience capabilities.
Secures exclusive three-year rights to Pathos Foundry platform.
Invests $55M to license large-scale patient dataset.
Bullish Signals
Bristol Myers Squibb expands its AI and data capabilities in neuroscience through a strategic collaboration with Pathos AI.
The company secured three-year exclusive rights to the Pathos Foundry platform specifically for its neuroscience portfolio.
BMS is investing $55 million to license a large-scale de-identified dataset covering hundreds of thousands of patients for research.
Bristol Myers Squibb is entering a critical week focused on late-stage clinical pipeline catalysts, following the announcement of positive Phase 3 results for admilparant in idiopathic pulmonary fibrosis (IPF) on October 12. The company's ALOFT-IPF trial demonstrated that a 60-milligram dose of the oral lysophosphatidic acid receptor 1 antagonist achieved a statistically significant improvement in forced vital capacity compared to placebo, supporting its potential as a first-in-class treatment.
Management plans to engage with health authorities regarding regulatory submissions for admilparant and anticipates progressive pulmonary fibrosis data from the ALOFT-PPF trial in early 2027. During the October 29 earnings call, executives highlighted these IPF results alongside interim Phase 3 data for RYZ101 in gastroenteropancreatic neuroendocrine tumors and positive outcomes for the CAR-T candidate arlo-cel, indicating a robust slate of registrational readouts expected throughout 2026.
Additional near-term clinical milestones include Phase 3 data for milvexian in secondary stroke prevention and Sotyktu in lupus, both scheduled before year-end. The company also intends to present open-label data from the ADEPT-1 and ADEPT-3 studies of Cobenfy for Alzheimer's disease psychosis at a conference in November, further diversifying its pipeline focus while managing development and patent risks.
π Admilparant Phase 3 showed significant lung function improvement at 60mg dose.
π¬ RYZ101 and arlo-cel show positive registrational readouts for key tumors.
π§ Milvexian and Sotyktu Phase 3 data expected before year-end.
βοΈ Investors focus on converting clinical wins into approvals and launches.
π Bristol Myers Squibb reported positive Phase 3 results for admilparant in idiopathic pulmonary fibrosis, showing statistically significant improvement in lung function with the 60-milligram dose.
π The ALOFT-IPF trial enrolled approximately 1,255 adults and demonstrated low discontinuations due to adverse events across treatment arms compared to placebo.
π Management expects to complete data evaluation for admilparant and engage with health authorities on potential regulatory submissions following the October 12 announcement.
π¬ Topline results from the fully enrolled ALOFT-PPF trial in progressive pulmonary fibrosis are expected in early 2027 according to company announcements.
𧬠Executives cited interim Phase 3 results for RYZ101 in gastroenteropancreatic neuroendocrine tumors and positive results for the CAR-T candidate arlo-cel as key registrational readouts.
π€ The company is actively engaging with the FDA on next steps for RYZ101 to advance its development program.
π§ Further catalysts include Phase 3 data for milvexian in secondary stroke prevention and Sotyktu in lupus scheduled before year-end.
ποΈ Bristol Myers Squibb plans to present open-label data from the ADEPT-1 and ADEPT-3 studies of Cobenfy at the Clinical Trials on Alzheimer's Disease conference in November.
π The third-quarter earnings call highlighted continued investment in manufacturing capacity alongside execution in the growth portfolio.
βοΈ Investors are focused on converting clinical wins into approvals and launches while managing development, regulatory, and patent risks.
Bullish Signals
Admilparant showed significant lung capacity improvement vs placebo at Week 52.
Admilparant had low adverse event discontinuations similar to placebo.
Positive Phase 3 admilparant results signal strong 2026 pipeline momentum.
RYZ101 and arlo-cel secured positive interim or final Phase 3 results.
Bullish Signals
Bristol Myers Squibb achieved a statistically significant improvement in forced vital capacity from baseline to Week 52 with the 60-milligram dose of admilparant in the ALOFT-IPF trial compared to placebo.
The company reported low discontinuations caused by adverse events across treatment arms for admilparant, which were similar to placebo, indicating a favorable safety profile.
Management described the positive Phase 3 results for admilparant as one of several positive registrational readouts expected in 2026, signaling strong pipeline momentum.
The company secured positive interim Phase 3 results for RYZ101 in gastroenteropancreatic neuroendocrine tumors and positive results for the CAR-T candidate arlo-cel.
The article compares AbbVie (ABBV) and Bristol Myers Squibb (BMY), concluding that while AbbVie has successfully transitioned from Humira with faster revenue growth of 10.20% versus BMY's 5.70%, BMY offers a significantly more attractive valuation. Bristol Myers trades at a forward price-to-earnings multiple of 9.36x compared to AbbVie's 16.39x, making it the cheaper option despite AbbVie's superior operating margin of 40.04% versus BMY's 34.42%.
Bristol Myers Squibb (NYSE: BMY) is highlighted as a better-priced stock with a net profit conversion rate of 18.87% against AbbVie's 9.80%, and an equity return of 46.60%. The company yields 4.10% compared to AbbVie's 2.66%, offering higher income potential for investors. However, the analysis notes that BMY faces its own patent cliff ahead with drugs like Eliquis and Revlimid facing erosion, which explains the market discount.
Institutional ownership data from Q2 2026 shows Bristol Myers was held by 74 hedge funds with a combined stake value of approximately $4.79 billion, down from $5.97 billion three months earlier. The article suggests that while AbbVie is the stronger operating business, BMY's combination of low valuation, high margins, and dividend yield makes it the superior investment choice for buyers seeking value in the pharmaceutical sector.
π BMY trades at forward P/E of 9.36x, cheaper than peers.
π° BMY converts 18.87% of revenue to net profit.
π Stock gained 35.23% over twelve months outperforming sector.
πΈ BMY offers 4.10% dividend yield versus AbbVie's 2.66%.
βοΈ Company maintains 46.60% return on equity despite patent cliffs.
π Bristol Myers Squibb (BMY) trades at a forward P/E multiple of 9.36x, significantly cheaper than AbbVie's 16.39x and Pfizer's 9.67x.
π° BMY converts 18.87% of revenue into net profit, nearly double AbbVie's 9.80% conversion rate.
π The stock has outperformed the sector with a 35.23% gain over twelve months, more than three times AbbVie's return.
πΈ BMY offers a higher dividend yield of 4.10% compared to AbbVie's 2.66%.
π Bristol Myers maintains a strong 46.60% return on equity despite facing upcoming patent cliffs for Eliquis and Revlimid.
π Hedge fund holdings in BMY decreased from $5.97 billion to $4.79 billion between Q1 and Q2 2026.
βοΈ While AbbVie grows faster at 10.20%, BMY provides better value with double-digit net margins and a lower valuation multiple.
Bullish Signals
Trades at forward P/E of 9.36x.
Converts 18.87% revenue to net profit.
Shares up 35.23% in last year.
Offers robust 4.10% dividend yield.
Achieves high 46.60% return on equity.
Risk Factors
Patent cliffs for Eliquis/Revlimid threaten revenue.
Hedge fund stakes dropped from $5.97B to $4.79B.
Bullish Signals
Bristol Myers Squibb trades at a forward P/E of 9.36x, offering a significant discount compared to AbbVie's 16.39x and the broader S&P 500 average.
The company converts 18.87% of revenue into net profit, nearly twice the rate of its rival AbbVie which sits at 9.80%.
Shares have appreciated 35.23% over the last twelve months, outperforming AbbVie and signaling market recognition of its value.
The stock yields a robust 4.10% dividend, providing higher income potential than AbbVie's 2.66% yield.
Bristol Myers achieves a high 46.60% return on equity, demonstrating efficient capital allocation despite patent headwinds.
Risk Factors
The company faces an imminent patent cliff with key assets Eliquis and Revlimid facing revenue erosion.
Hedge fund interest has declined, with cumulative stake value dropping from $5.97 billion to $4.79 billion in three months.
Bristol Myers Squibb reported a strong third-quarter performance with revenue rising 7% year-over-year to $13.07 billion, surpassing analyst expectations of $12.75 billion. The company's Growth Portfolio drove significant momentum, with Eliquis revenue surging 25% to $4.69 billion, while the Legacy Portfolio grew 1% despite headwinds from older medicines.
Despite the top-line beat, management lowered its adjusted earnings per share (EPS) guidance for 2026 to a range of $6.35 to $6.55, down from the previous forecast of $6.75 to $7.00. This reduction was primarily attributed to one-time acquisition-related charges and a specific charge linked to the termination of a contract, which also contributed to a decline in adjusted gross margin to 68.4%.
Looking ahead, the company raised its full-year 2026 revenue outlook to between $49.75 billion and $50.25 billion, reflecting confidence in its pipeline and commercial execution. Key future catalysts include the potential expansion of Cobenfy into Alzheimer's disease treatment and the development of milvexian, with data expected next year.
In the realm of oncology, Bristol Myers Squibb is working with the FDA to resume enrollment in trials for zolacabtagene autoleucel in early 2027. The company had previously paused these studies in September following a patient death but identified a manufacturing reagent as the root cause and adjusted the process accordingly.
π Q3 revenue hit $13.07B, up 7% year-over-year.
π Eliquis sales jumped 25% to $4.69B.
π Adjusted EPS guidance lowered to $6.35β$6.55 for 2026.
π° Full-year 2026 revenue outlook raised to $49.75Bβ$50.25B.
π¬ Zolacabtagene autoleucel trials resume early 2027.
π Bristol Myers Squibb reported third-quarter revenue of $13.07 billion, representing a 7% year-over-year increase that exceeded analyst forecasts.
π Eliquis sales surged 25% to $4.69 billion, serving as the primary driver for growth within the company's Growth Portfolio.
π Management lowered adjusted EPS guidance for 2026 to $6.35β$6.55 due to acquisition-related charges and a contract termination fee.
π° The company raised its full-year 2026 revenue outlook to a range of $49.75 billion to $50.25 billion.
π¬ Bristol Myers Squibb plans to resume zolacabtagene autoleucel trials in early 2027 after resolving a manufacturing safety issue linked to a patient death.
π§ Future growth catalysts include the potential expansion of Cobenfy into Alzheimer's disease and the development of milvexian.
Bullish Signals
Q3 revenue beat expectations at $13.07 billion.
Eliquis sales surged 25% to $4.69 billion.
Raised full-year 2026 guidance to $49.75β$50.25 billion.
Risk Factors
EPS guidance lowered to $6.35β$6.55 due to acquisition charges.
Gross margin fell to 68.4% from 72.9% amid mix changes.
Bullish Signals
Bristol Myers Squibb beat third-quarter revenue expectations with $13.07 billion in sales, driven by a 25% surge in Eliquis revenue to $4.69 billion.
The company raised its full-year 2026 revenue guidance to $49.75β$50.25 billion, signaling strong commercial momentum and demand for its growth portfolio.
Risk Factors
Adjusted EPS guidance was lowered to $6.35β$6.55 from the prior range of $6.75β$7.00 due to significant acquisition-related charges.
Adjusted gross margin declined to 68.4% from 72.9%, reflecting unfavorable product mix changes and a one-time charge associated with terminating a contract.
Bristol Myers Squibb reported third-quarter 2026 results that exceeded analyst expectations, driven by strong performance across its Growth and Legacy portfolios. The company posted revenue of USD 13.07 billion, a 7 percent year-over-year increase that surpassed the consensus estimate of USD 12.72 billion. Adjusted earnings per share reached USD 1.35, significantly beating the cited analyst estimate of USD 1.09.
Key drivers included robust growth in the Growth Portfolio, which generated USD 7.7 billion in revenue, up 12 percent year over year. Specific products contributing to this expansion include Opdivo Qvantig, Breyanzi, Reblozyl, Camzyos, and Opdualag. The Legacy Portfolio produced USD 5.4 billion, while Eliquis revenue rose notably by 25 percent to reach USD 4.69 billion.
Looking ahead, Bristol Myers Squibb raised its full-year 2026 sales forecast to a range of USD 49.75 billion to USD 50.25 billion, up from the previous guidance of USD 49.0 billion to USD 50.0 billion. However, management lowered adjusted earnings guidance to USD 6.35 to USD 6.55 per share due to acquired in-process research and development charges and licensing income impacts.
Financial metrics showed a decline in adjusted gross margin to 68.4 percent from 72.9 percent in the prior-year quarter, attributed to product mix changes and a one-time charge related to contract termination. Investors are weighing the strength of sales growth against these lower near-term earnings visibility factors as the company navigates deal-related charges.
π Q3 2026 revenue hit USD 13.07 billion, beating estimates with a 7% year-over-year increase.
π° Adjusted EPS reached USD 1.35, significantly surpassing the consensus estimate of USD 1.09.
π Growth Portfolio revenue surged to USD 7.7 billion, driven by Opdivo Qvantig and Breyanzi.
β οΈ Full-year earnings guidance lowered to USD 6.35β6.55 due to IPRD charges and licensing income.
π Adjusted gross margin declined to 68.4% from 72.9% due to product mix changes.
π Bristol Myers Squibb reported Q3 2026 revenue of USD 13.07 billion, a 7 percent year-over-year increase that beat analyst estimates.
π° Adjusted earnings per share reached USD 1.35, significantly surpassing the consensus estimate of USD 1.09.
π The Growth Portfolio generated USD 7.7 billion in revenue, up 12 percent year over year, driven by key products like Opdivo Qvantig and Breyanzi.
π Eliquis revenue surged 25 percent to USD 4.69 billion within the Legacy Portfolio.
π The company raised its full-year 2026 sales guidance to a range of USD 49.75 billion to USD 50.25 billion.
β οΈ Adjusted earnings guidance was lowered to USD 6.35 to USD 6.55 per share due to acquired IPRD charges and licensing income.
π Adjusted gross margin declined to 68.4 percent from 72.9 percent, primarily due to product mix changes and a one-time contract termination charge.
π’ The stock traded at EUR 56.35 on Lang & Schwarz as of Friday, October 30, 2026.
Bullish Signals
Q3 revenue hit $13.07B, up 7% year-over-year.
Risk Factors
Guidance lowered to $6.35-$6.55 due to acquired R&D charges.
Simply Wall St has reduced its fair value estimate for Bristol-Myers Squibb (BMY) from US$66.71 to US$65.25, reflecting a more cautious outlook on the company's long-term revenue growth and valuation multiples. The analysis assumes a decline in long-term revenue growth of 7.39% compared to a prior estimate of 6.60%, while projecting a net profit margin increase to 21.52% from 20.59%. The assumed future P/E multiple has been lowered to 19.75x from 20.58x, with the discount rate remaining stable at 7.24%.
Analyst sentiment remains highly divergent regarding BMY's pipeline and corporate strategy. Bullish firms like Piper Sandler, Jefferies, and Guggenheim cite strong potential in late-stage assets such as admilparant for idiopathic pulmonary fibrosis (IPF) and value from business development activity. Conversely, cautious analysts including Leerink, Morgan Stanley, and Cantor Fitzgerald express concerns over execution risks on key programs like milvexian and Cobenfy, while Wells Fargo highlights liver safety questions surrounding admilparant as a significant overhang.
Recent clinical data has presented a mixed picture for the biopharmaceutical giant. Positive late-stage oncology readouts included Phase 3 results for izalontamab in breast and lung cancer showing significant risk reduction, alongside FDA approval support for CELMoD ZENBEXUS in multiple myeloma. However, interim Phase 1 data for zola cel in multiple sclerosis coincided with a patient death from septic pneumonia, which contributed to a roughly 2.5% share price decline. The company also expanded its AI and real-world data capabilities through new agreements with Tempus AI and Pathos AI.
π Simply Wall St lowered BMY fair value to US$65.25 due to reduced growth assumptions.
π BMY showed 59% disease progression risk reduction with izalontamab in breast cancer.
π FDA supported CELMoD ZENBEXUS combination therapy for multiple myeloma approval.
𧬠Strategy offsets patent cliffs via oncology and neuroscience assets like milvexian.
π Simply Wall St lowered BMY's fair value estimate from US$66.71 to US$65.25, citing a reduced long-term revenue growth assumption of 7.39% and a lower P/E multiple of 19.75x.
π¬ Bullish analysts highlight admilparant as a potential blockbuster for idiopathic pulmonary fibrosis, with Jefferies lifting peak sales estimates and William Blair describing a meaningful market opportunity.
β οΈ Wells Fargo flags liver safety concerns around admilparant as a meaningful overhang that could impact the drug's commercialization and regulatory path.
π BMY reported positive Phase 3 data for izalontamab in advanced breast cancer showing a 59% reduction in disease progression risk versus chemotherapy.
π The company received FDA approval support for CELMoD ZENBEXUS in combination with daratumumab and dexamethasone based on MRD negative complete response in multiple myeloma.
π Interim Phase 1 Breakfree-2 data for zola cel in multiple sclerosis showed early efficacy signals but coincided with a patient death from septic pneumonia, triggering a 2.5% stock decline.
π€ Bristol-Myers Squibb announced expanded AI and real-world data agreements with Tempus AI and Pathos AI, securing exclusive access to the Pathos Foundry platform in neuroscience.
π Analyst consensus ranges widely from US$40s to US$82, with Piper Sandler, Jefferies, and Guggenheim maintaining constructive targets despite recent trims by Leerink and Morgan Stanley.
𧬠The company's strategy focuses on offsetting pressure from older drugs facing patent cliffs through growth in oncology, neuroscience, and immunology assets like milvexian and Cobenfy.
Bullish Signals
Analysts maintain high price targets up to US$82 citing pipeline strength.
Jefferies lifted peak sales estimate for idiopathic pulmonary fibrosis opportunity.
Phase 3 ACTION 1 data for RYZ101 showed positive oncology readouts.
FDA supported approval of CELMoD ZENBEXUS in multiple myeloma.
Phase 3 EXCALIBER RRMM data doubled median progression-free survival versus chemo.
Risk Factors
Fair value cut to $65.25 due to lower growth and P/E assumptions.
Liver safety risks for Admilparant pose development overhangs.
Zola Cel patient death linked to interim Phase 1 data.
Analysts cite execution concerns on key programs like Admilparant.
Admilparant shows confounding efficacy with limited differentiation.
Bullish Signals
Bullish analysts including Piper Sandler, Jefferies, and Guggenheim maintain high price targets up to US$82, citing constructive views on the broader pipeline and potential business development activity.
Jefferies lifted its admilparant peak sales estimate, describing it as a potential blockbuster market opportunity for idiopathic pulmonary fibrosis supported by ALOFT-IPF data.
Phase 3 ACTION 1 data for radiopharmaceutical RYZ101 in gastroenteropancreatic neuroendocrine tumors provided positive late-stage oncology readouts supporting the company's growth portfolio.
The FDA supported approval of CELMoD ZENBEXUS in multiple myeloma based on MRD negative complete response, validating the combination therapy with daratumumab and dexamethasone.
Phase 3 EXCALIBER RRMM data for CELMoD ZENBEXUS demonstrated a doubling of median progression-free survival versus chemotherapy in lung cancer contexts.
Risk Factors
Simply Wall St reduced its fair value estimate from US$66.71 to US$65.25, driven by a revised long-term revenue growth assumption declining to 7.39% and a lower P/E multiple of 19.75x.
Wells Fargo highlights liver safety questions around admilparant, describing hepatic safety as a meaningful overhang that poses a risk to the program's development.
Interim Phase 1 Breakfree-2 data for zola cel in multiple sclerosis coincided with a patient death from septic pneumonia, which contributed to a roughly 2.5% share price decline.
Cautious analysts like Leerink, Morgan Stanley, and Cantor Fitzgerald express concerns around execution on key programs including admilparant, milvexian, and Cobenfy.
RBC notes that while the ALOFT-IPF efficacy profile is encouraging, it is confounding with limited differentiation expected from higher doses of admilparant.
Bristol-Myers Squibb (BMY) shares have risen 48.3% over the past year, trading at US$61.61. The article analyzes whether this price is justified by future cash generation, noting that while recent clinical updates in oncology and neuroscience offer potential upside, a patient death in an early CAR T multiple sclerosis trial has introduced risk concerns.
A Discounted Cash Flow (DCF) model projects an intrinsic value substantially above the current US$61.61 share price based on latest twelve-month free cash flow of approximately $11.5 billion. However, community narratives suggest a conflicting view, with one prominent thesis labeling the stock as 116% overvalued due to high entry prices relative to quality.
Simply Wall St highlights three specific warning signs for investors to consider before making decisions, emphasizing that valuation alone does not capture the full picture of the company's prospects. The analysis relies on historical data and analyst forecasts rather than recent price-sensitive announcements or qualitative material.
π BMY stock rose 48.3% year-over-year, closing at US$61.61.
π° Company generated $11.5 billion in latest twelve-month free cash flow.
β οΈ Patient death in MS trial created market risk discount for BMY.
π Community narrative rates BMY stock 116% overvalued currently.
π§ Oncology and neuroscience data could reshape BMY future revenue.
π BMY stock has climbed 48.3% over the past year, closing at US$61.61.
π° The company generated approximately $11.5 billion in latest twelve-month free cash flow.
β οΈ A patient death in an early CAR T multiple sclerosis trial has led to a market risk discount.
π One community narrative rates the stock as 116% overvalued at current levels.
π Simply Wall St identifies three specific warning signs for investors to review.
π§ Recent clinical data in oncology and neuroscience could reshape future revenue expectations.
Bullish Signals
Generated $11.5B FCF.
Cell therapy data boosts oncology outlook.
Risk Factors
Patient death in MS trial discounts future cash flows.
Stock deemed 116% overvalued by community narratives.
Bullish Signals
The company generated approximately $11.5 billion in latest twelve-month free cash flow, providing a strong base for valuation models.
New clinical data in cell therapies and antibody drug conjugates may reshape positive expectations for future oncology revenue streams.
Risk Factors
A patient death in an early CAR T multiple sclerosis trial has caused the market to apply a clear risk discount to future cash flows.
One prominent community narrative labels the stock as 116% overvalued, citing that current prices exceed entry filters.
Drug pricingFinancial outlookPatent expiryAI-generated analysis
Bristol-Myers Squibb (BMY) shares have gained 46.5% over the past year, trading at US$61.48 after Q2 2026 results showed revenue rising to US$12,973m and net income reaching US$3,317m. This performance aligns with optimistic valuation models that project a 22.4% profit margin and a 14.4x future P/E ratio, suggesting the market has priced in successful delivery from the late-stage oncology portfolio despite lingering concerns about patent cliffs on key assets like Eliquis and Opdivo.
The article highlights a divergence between bullish and bearish narratives regarding BMY's future value. While optimistic views assume newer drugs will seamlessly replace earnings from aging blockbusters, cautious analysts warn that loss of exclusivity and pricing pressure could erode the revenue mix and margin profile. The core investment thesis relies on the company's ability to convert its large late-stage pipelineβincluding assets like milvexian, admilparant, and CELMoDsβinto durable post-loss-of-exclusivity revenue that offsets potential setbacks, delays, or safety concerns.
Investors are advised to track net margin in filings against claims of expansion to ensure higher earnings stem from the core portfolio rather than one-off shifts. The broader lesson for drug makers is the necessity of a spread of therapies across specialties to mitigate reliance on single blockbusters. While BMY faces challenges regarding trial delays and safety questions, the current market price implies confidence that the newer portfolio will sustain growth even as patent protections expire.
π BMY shares rose 46.5% YTD with Q2 2026 revenue of US$12,973m and net income of US$3,317m.
π Net margin expanded to 25.6% in Q2 2026, approaching the optimistic 22.4% target valuation assumption.
β οΈ Bearish analysts warn loss of exclusivity for Eliquis and Opdivo could erode revenue mix and margins.
π¬ Pipeline assets milvexian, admilparant, arlo-cel, and CELMoDs must convert to durable revenue to offset declines.
π° Fair Value ranges from US$53 (bullish) to US$34 (bearish) based on P/E and debt concerns.
π Bristol-Myers Squibb shares rose 46.5% over the past year to trade at US$61.48, reflecting strong Q2 2026 performance with revenue of US$12,973m and net income of US$3,317m.
π The company achieved a net margin of 25.6% in Q2 2026, up significantly from 10.7% a year earlier, aligning with optimistic valuation assumptions of a 22.4% target margin.
β οΈ Bearish analysts warn that loss of exclusivity for key drugs like Eliquis and Opdivo combined with pricing pressure could continue eroding the revenue mix and margin profile.
π¬ The investment case hinges on converting the late-stage pipeline, including assets milvexian, admilparant, arlo-cel, and CELMoDs, into durable revenue to offset blockbuster declines.
π° Optimistic valuation models price BMY at a Fair Value of US$53 based on 14.4x future P/E, while cautious views suggest a lower value of US$34 due to debt concerns.
π Investors must verify if margin expansion comes from the core portfolio or one-off shifts by tracking net margins in upcoming filings against company claims.
Bullish Signals
Revenue rose to US$12,973m with net income at US$3,317m.
Net margin expanded to 25.6% versus 10.7% prior year.
Shares gained 46.5% as oncology portfolio replaces aging drugs.
Risk Factors
Key drug exclusivity loss erodes revenue mix and margins.
Trial delays on milvexian/admilparant threaten earnings handover.
Bullish Signals
Bristol-Myers Squibb delivered strong Q2 2026 results with revenue rising to US$12,973m and net income reaching US$3,317m, marking a significant improvement over the prior year.
The company achieved a robust net margin of 25.6% in Q2 2026 compared to 10.7% a year earlier, validating optimistic assumptions about profitability expansion.
Shares have appreciated 46.5% over the past year, trading at US$61.48, indicating market confidence that the late-stage oncology portfolio is successfully replacing earnings from aging blockbusters.
Risk Factors
Bearish analysts expect loss of exclusivity and pricing pressure on key drugs to continue eroding Bristol-Myers Squibb's revenue mix and margin profile despite newer portfolio growth.
The company faces ongoing concerns regarding trial delays, safety questions, and timelines for late-stage assets like milvexian and admilparant that could challenge a smooth handover of earnings.
Bristol-Myers Squibb (NYSE:BMY) reported a 40% increase in second-quarter adjusted earnings per share, rising from $1.46 to $2.04, driven by strong growth in its Growth Portfolio which now accounts for roughly 58% of quarterly revenue at $7.6 billion. Key drivers included significant gains in Reblozyl (up 29%), Breyanzi (up 41%), and Camzyos (up 60%). Management raised its annual revenue outlook to between $49 billion and $50 billion, and adjusted EPS guidance to a range of $6.75 to $7.00.
However, the reported earnings jump is partially obscured by accounting adjustments; removing a one-time net acquisition-related R&D charge from the prior quarter reveals that underlying comparable earnings were approximately flat at roughly $2.03 per share. Despite this, BMY's legacy portfolio continues to face headwinds with overall revenue falling 4% to $5.42 billion, led by steep declines in Revlimid (down 49%) and Pomalyst/Imnovid (down 71%). The company trades at a forward multiple of about 9.36x earnings.
In a comparative analysis with Pfizer, BMY appears cheaper on an earnings basis despite showing stronger recent revenue growth than its competitor. While Pfizer also demonstrated operational growth in non-COVID products like Padcev and Lorbrena, it faces the challenge of offsetting declining COVID-related sales against rising non-vaccine revenue. The article concludes that neither company's headline EPS fully captures the complexities of their ongoing product transitions and portfolio shifts.
π BMY Q2 adjusted EPS rose 40% to $2.04 as revenue grew 6% to $13.0 billion.
π Growth Portfolio expanded 15% to $7.6 billion, now comprising 58% of quarterly revenue.
π Management raised annual guidance to $49β$50B revenue and $6.75β$7.00 adjusted EPS.
β οΈ Legacy portfolio declined 4% to $5.42B, with Revlimid dropping 49% and Pomalyst/Imnovid falling 71%.
π° BMY trades at 9.36x forward earnings, slightly cheaper than Pfizer despite stronger recent growth.
π Bristol-Myers Squibb reported a 40% rise in second-quarter adjusted earnings per share to $2.04, driven by a 6% increase in total revenue to $13.0 billion.
π The company's Growth Portfolio grew 15% to $7.6 billion, now representing approximately 58% of quarterly revenue with strong performance from Reblozyl, Breyanzi, and Camzyos.
π Management raised its annual revenue guidance to $49β$50 billion and adjusted EPS guidance to $6.75β$7.00, signaling confidence in the non-COVID pipeline.
β οΈ The reported earnings growth is partially offset by a legacy portfolio decline of 4% to $5.42 billion, with Revlimid dropping 49% and Pomalyst/Imnovid falling 71%.
π Adjusting for a one-time $0.57-per-share R&D charge from the prior quarter reveals that underlying comparable earnings were effectively flat at approximately $2.03 per share.
π° Bristol-Myers Squibb trades at a forward multiple of 9.36x earnings, appearing slightly cheaper than Pfizer's 9.67x despite stronger recent revenue growth.
π The company successfully diversified its revenue base, reducing reliance on any single blockbuster drug through the expansion of its Growth Portfolio.
Bullish Signals
Q2 adjusted EPS rose 40% to $2.04.
Growth Portfolio grew 15% to $7.6 billion.
Management raised annual revenue and EPS guidance.
Stock trades at attractive 9.36x forward multiple.
Risk Factors
Earnings jump is an accounting artifact; underlying comparable earnings flat at $2.03/share.
Bullish Signals
Bristol-Myers Squibb reported a 40% increase in second-quarter adjusted earnings per share to $2.04, driven by strong growth in its diversified Growth Portfolio.
The company's Growth Portfolio grew 15% to $7.6 billion, now accounting for roughly 58% of quarterly revenue with significant gains in Reblozyl (29%), Breyanzi (41%), and Camzyos (60%).
Management raised its annual revenue outlook to $49β$50 billion and adjusted EPS guidance to $6.75β$7.00, indicating a successful transition away from legacy products.
The stock trades at a forward multiple of 9.36x earnings, presenting a potentially attractive valuation relative to peers like Pfizer.
Risk Factors
The reported 40% earnings jump is partially an accounting artifact; removing a one-time $0.57-per-share R&D charge from the prior quarter shows underlying comparable earnings were flat at roughly $2.03 per share.
The legacy portfolio declined 4% to $5.42 billion, with major declines in Revlimid (down 49%) and Pomalyst/Imnovid (down 71%), creating pressure on overall revenue growth.
Despite strong Growth Portfolio performance, the company must continue to replace substantial lost sales from aging medicines to sustain long-term earnings acceleration.
The article compares Bristol-Myers Squibb (BMY) and Johnson & Johnson (JNJ), noting that BMY focuses on specialized biopharmaceuticals in oncology, hematology, and cardiovascular health, while JNJ operates as a diversified conglomerate with significant medical technology segments. In fiscal year 2025, Bristol-Myers Squibb reported revenue of approximately $48.2 billion, a slight decrease of 0.2% from the prior year, alongside a net income recovery to roughly $7.1 billion after a previous loss.
Bristol-Myers Squibb holds total cash of $11 billion against over $45 billion in debt, maintaining an 18.8% profit margin and a 34.4% trailing operating margin. The company faces specific headwinds including pricing pressure from the Inflation Reduction Act on key products like Eliquis and Pomalyst, patent expirations for major drugs, and legal challenges regarding its Celgene acquisition integration.
In contrast, Johnson & Johnson reported revenue of nearly $94.2 billion in FY 2025, a 6% increase, with net income reaching close to $26.8 billion. JNJ has cash of $20.7 billion and debt exceeding $49 billion, operating with a 16.2% profit margin and a 25% trailing operating margin. The article highlights that BMY offers a higher dividend yield of 4.1%, whereas JNJ is a Dividend King with 64 consecutive years of payout increases.
The analysis concludes that while Bristol-Myers Squibb appears cheaper on a multiple basis, it carries risks related to finding new drug hits to counter patent cliffs. Conversely, Johnson & Johnson benefits from larger revenue opportunities and stability following the spin-off of its consumer healthcare division in August 2023, though it faces its own litigation and competition challenges.
π FY 2025 revenue dipped 0.2% to $48.2 billion.
π° Net income recovered to $7.1 billion after prior loss.
π IRA pricing pressure impacts Eliquis and Pomalyst sales.
Bristol Myers Squibb (BMY) maintains a 4.2% dividend yield supported by 17 consecutive annual increases and 94 years of payments, though recent growth faces headwinds from patent expirations and significant debt levels. The company reported second-quarter EPS of $2.04, exceeding analyst estimates, and raised its 2026 non-GAAP EPS guidance to $6.75-$7.00. Management highlighted that the current dividend consumes approximately 36% to 37% of guided earnings, providing a comfortable cushion for future payouts while allowing for debt reduction.
The core challenge for BMY's dividend trajectory lies in the impending loss of sales from its blockbuster drug Eliquis, which is projected to decline by $1.5 billion to $2 billion by 2027 due to generic competition following its patent expiry in April 2028. The company is relying on milvexian to replace Eliquis revenue, but the drug's atrial fibrillation trial data has been delayed until the first quarter of 2027. Additionally, BMY carries approximately $43.1 billion in total debt, which constrains its ability to accelerate dividend raises compared to peers.
Despite these risks, BMY demonstrates resilience through strong performance in its Growth Portfolio, where sales rose 15% to $7.56 billion in the second quarter. Key growth drivers include Camzyos (up 60%), Breyanzi (up 41%), and Reblozyl (up 29%), which are offsetting steep declines in older drugs like Revlimid, which fell 49%. The stock has gained 45% over the past year, pushing the yield down slightly, but analysts view the payout as safe given the company's robust cash flow of roughly $3.4 billion per quarter and its commitment to returning capital to shareholders.
π BMY raised quarterly dividend to $0.63 for 94th consecutive year of payments.
π° Q2 EPS beat estimates at $2.04 with 2026 guidance raised to $6.75-$7.00.
π‘οΈ Total debt is $43.1 billion, reduced by $1.2 billion in the latest quarter.
β οΈ Eliquis sales face $1.5B decline by 2027 due to generic competition and patent expiry.
π¬ Milvexian atrial fibrillation trial data delayed until Q1 2027, creating revenue replacement uncertainty.
π BMY raised its quarterly dividend to $0.63 per share, marking the 17th consecutive annual increase and the 94th year of payments.
π° The company reported second-quarter EPS of $2.04, beating the $1.597 estimate, and raised 2026 non-GAAP EPS guidance to $6.75-$7.00.
π‘οΈ Total debt stands at approximately $43.1 billion, with the company paying down $1.2 billion in the most recent quarter.
β οΈ Eliquis sales are expected to decline by $1.5 billion to $2 billion by 2027 due to generic competition and patent expiry in April 2028.
π¬ The replacement drug milvexian has delayed its atrial fibrillation trial data until the first quarter of 2027, creating uncertainty for future revenue replacement.
π Growth Portfolio sales surged 15% to $7.56 billion in Q2, driven by Camzyos (+60%), Breyanzi (+41%), and Reblozyl (+29%).
π Older drugs face significant headwinds, with Revlimid sales falling 49% and Pomalyst dropping 71% year-over-year.
π΅ Operating cash flow reached approximately $3.4 billion for the quarter, supporting a dividend that uses only 36-37% of guided earnings.
π Shares have risen 45% over the past year and 17.26% year-to-date, reflecting investor confidence in the company's growth strategy.
Bullish Signals
Dividend raised 17th year; payout ratio just 36-37%.
Q2 EPS beat $2.04; full-year guidance raised to $6.75-$7.00.
Growth Portfolio sales up 15% to $7.56B in Q2.
Operating cash flow ~$3.4B/quarter funds dividend and debt reduction.
Paid down $1.2B debt; disciplined balance sheet management.
Risk Factors
Eliquis sales projected to drop $1.5-$2B by 2027.
Milvexian trial data delayed to Q1 2027.
Revlimid and Pomalyst sales fell 49% and 71%.
$43.1B debt limits dividend growth vs peers.
Bullish Signals
Bristol Myers Squibb raised its quarterly dividend to $0.63 per share for the 17th consecutive year, with a payout ratio of only 36-37% against raised 2026 EPS guidance.
Second-quarter earnings beat estimates at $2.04 EPS, and management increased full-year non-GAAP EPS guidance to $6.75-$7.00, signaling strong operational performance.
The Growth Portfolio delivered robust 15% sales growth in Q2, reaching $7.56 billion, with standout performers Camzyos (+60%) and Breyanzi (+41%).
Strong operating cash flow of approximately $3.4 billion per quarter provides ample liquidity to fund the dividend and reduce the $43.1 billion debt load.
The company successfully paid down $1.2 billion in debt during the quarter, demonstrating a disciplined balance sheet management strategy.
Risk Factors
Eliquis is projected to lose $1.5 billion to $2 billion in sales by 2027 due to generic competition and patent expiry in April 2028.
The critical replacement drug milvexian has delayed its atrial fibrillation trial data until Q1 2027, introducing timing risk for revenue replacement.
Older blockbuster drugs are shrinking rapidly, with Revlimid sales falling 49% and Pomalyst dropping 71% year-over-year in the second quarter.
The company carries a substantial $43.1 billion debt load, which limits its ability to accelerate dividend increases compared to peers like Pfizer.
The article analyzes Bristol Myers Squibb (NYSE: BMY) as a core component of a diversified dividend portfolio, suggesting an investment of approximately $70,000 to generate roughly $2,940 in annual income based on a 4.2% yield. The author argues that while BMY offers attractive current income, investors should avoid concentrating solely on high-yield stocks like Pfizer due to the risk of dividend cuts or patent expirations.
Bristol Myers Squibb faces specific risks highlighted in the text, including the loss of patent protection for its major drugs Opdivo and Eliquis in 2028. Despite these challenges, the company is noted for having a strong drug pipeline that it must successfully bring to market to maintain long-term revenue generation and support its dividend payments.
The article positions BMY alongside peers like Johnson & Johnson, AbbVie, and Amgen as essential diversifiers against sector-wide risks such as patent cliffs. It concludes that including BMY in a balanced portfolio of five pharma stocks significantly reduces the impact of any single company's potential dividend cut or product failure compared to holding a concentrated position in one high-yield stock.
π Strong pipeline must commercialize to replace patent revenue and sustain dividends.
π BMY softens overall portfolio risk versus single high-yield stock reliance.
π Bristol Myers Squibb offers a 4.2% dividend yield, generating approximately $2,940 annually for a $70,000 investment within the proposed diversified portfolio.
β οΈ The company faces patent expiration risks in 2028 as it loses protection on key drugs Opdivo and Eliquis, requiring successful pipeline development to offset income loss.
π‘οΈ Including BMY in a five-stock pharma portfolio helps mitigate the specific risk of a dividend cut that would disproportionately affect concentrated high-yield positions like Pfizer.
π Bristol Myers Squibb maintains a strong drug pipeline that it must successfully commercialize to replace revenue from expiring patents and sustain its dividend.
π The article notes that BMY's inclusion softens overall portfolio risk compared to relying on a single high-yield stock with potential earnings shortfalls.
Bullish Signals
Offers 4.2% dividend yield for stable income.
Diversifies portfolio against peer dividend cut risks.
Risk Factors
Major drug patents expire in 2028, including Opdivo and Eliquis.
Bullish Signals
Bristol Myers Squibb provides a 4.2% dividend yield, contributing $2,940 annually to a diversified five-stock pharma portfolio designed to generate stable monthly income.
The company is presented as a necessary diversifier against the specific risk of dividend cuts that threaten high-yield peers like Pfizer.
Risk Factors
Bristol Myers Squibb faces significant patent expiration risks in 2028 with the loss of protection on its major drugs Opdivo and Eliquis.
The article compares Bristol Myers Squibb (BMY) and Pfizer, concluding that Pfizer is the preferred investment despite both facing patent cliffs. It highlights BMY's recent recovery in net income to approximately $7.1 billion in FY 2025, a slight revenue decrease of 0.2% to $48.2 billion, and a debt-to-equity ratio of 2.6x. The company maintains strong free cash flow of nearly $12.8 billion.
Bristol Myers Squibb is noted for its leadership in oncology and neuroscience, with strategic alliances including BioNTech and Johnson & Johnson. However, the stock faces significant headwinds from pricing pressure under the Inflation Reduction Act affecting products like Eliquis and Pomalyst, alongside patent expirations and generic competition.
Specific risks identified for BMY include a revived $6.7 billion lawsuit regarding contingent value rights from its Celgene acquisition and the termination of an early-stage leukemia clinical trial. While the company raised its full-year revenue outlook and newer brands are gaining traction, the author argues that BMY faces a longer stretch of uncertainty compared to Pfizer's more visible post-patent roadmap.
The analysis suggests that while BMY is slightly more affordable on a forward earnings basis, Pfizer offers a clearer path forward with growth in non-COVID products and an obesity drug portfolio. The Motley Fool analyst team did not include Bristol Myers Squibb in their top 10 stocks for immediate purchase, citing these structural challenges.
π FY 2025 revenue dipped slightly to $48.2 billion.
π° Net income recovered to $7.1 billion with 14.6% margin.
π¦ Debt-to-equity stands at 2.6x; free cash flow hit $12.8B.
β οΈ Reviled by $6.7B lawsuit over Celgene contingent value rights.
π Future revenue pressured by patent cliffs and pricing reforms.
π Bristol Myers Squibb reported FY 2025 revenue of nearly $48.2 billion, a slight decrease of roughly 0.2% compared to the prior year.
π° The company achieved a net income recovery to close to $7.1 billion in FY 2025, resulting in a net margin of approximately 14.6%.
π¦ As of December 2025, BMY maintains a debt-to-equity ratio of roughly 2.6x and generated free cash flow of nearly $12.8 billion.
βοΈ The company faces intense pricing pressure from the Inflation Reduction Act impacting Medicare-set prices for key products like Eliquis and Pomalyst.
β οΈ Significant legal exposure exists due to a recently revived $6.7 billion lawsuit regarding contingent value rights linked to its Celgene acquisition.
π¬ Operational risks include the recent termination of an early-stage leukemia clinical trial within the oncology pipeline.
π BMY raised its full-year revenue outlook, and newer growth brands are currently gaining market traction.
π Eliquis continues to defy expectations with stronger-than-anticipated growth despite regulatory pricing pressures.
π The article notes that BMY faces significant revenue pressure from patent losses in the years ahead alongside drug pricing reforms.
π The Motley Fool analyst team did not identify Bristol Myers Squibb as one of their top 10 stocks for investors to buy now.
Bullish Signals
Net income recovered to $7.1 billion in FY 2025.
Free cash flow reached nearly $12.8 billion by Dec 2025.
New growth brands offset patent expiration impacts on legacy products.
Eliquis defies expectations with stronger-than-anticipated growth.
Risk Factors
IR Act pricing pressure hits Eliquis and Pomalyst.
Patent expirations and biosimilars erode revenue.
$6.7B revived lawsuit over Celgene acquisition risks.
Oncology pipeline risk from terminated leukemia trial.
Long-term uncertainty from patent losses ahead.
Bullish Signals
Net income recovered to close to $7.1 billion in FY 2025, marking a recovery from the net loss reported in the prior fiscal year.
The company generated strong free cash flow of nearly $12.8 billion as of its December 2025 balance sheet.
Bristol Myers Squibb raised its full-year revenue outlook, signaling improved near-term momentum for investors.
Newer growth brands are gaining traction, helping to offset the impact of patent expirations on legacy products.
Eliquis continues to defy expectations with stronger-than-anticipated growth despite regulatory pricing pressures.
Risk Factors
The company faces intense pricing pressure from the Inflation Reduction Act, which has led to Medicare-set prices for major products like Eliquis and Pomalyst.
Patent expirations for major products remain a primary concern, alongside ongoing generic and biosimilar competition eroding revenue.
The company deals with significant legal exposure, including a recently revived $6.7 billion lawsuit regarding contingent value rights linked to its Celgene acquisition.
There are inherent risks in the oncology pipeline highlighted by the recent termination of an early-stage leukemia clinical trial.
The article suggests BMY faces a longer stretch of uncertainty compared to competitors, with significant revenue pressure from patent losses in the years ahead.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)